| 摘要 |
<p>Drugs for topical administration which contain an EP4 agonist as the active ingredient for preventing and/or treating diseases in association with bone mass loss. EP4 agonists typified by compounds with the prostaglandin skeleton have an effect of promoting osteogenesis. Thus, topical administration thereof is highly useful in preventing and/or treating diseases in association with bone mass loss (for example, bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Behcet' s disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone transplantation).</p> |
